SAN DIEGO , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2019 financial results after
– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and medical affairs veteran Dr. Bridget Martell named acting Chief Medical Officer – – Dr.
SAN DIEGO , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced its participation at the 38th Annual J.P. Morgan Healthcare Conference .
Company strengthens leadership team to support pre-commercial efforts and launch optimization SAN DIEGO , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer,
– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC – – Registration-directed AIM-HN trial expected to complete enrollment in first quarter of 2021 – SAN DIEGO , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.
– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR) observed in AITL patients with KIR mutations, a CXCL pathway-associated biomarker – – Company to conduct a single-arm, Phase 2
SAN DIEGO , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer,
SAN DIEGO , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer,
Data from Phase 2 trial of tipifarnib in AITL accepted for oral presentation SAN DIEGO , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced
– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of tipifarnib in AITL accepted for oral presentation at ASH 2019 – – Initiation of first-in-class menin-MLL inhibitor KO-539 gives
